Harold Roman

38 Flips | 1 Magazine | @HaroldRoman | Keep up with Harold Roman on Flipboard, a place to see the stories, photos, and updates that matter to you. Flipboard creates a personalized magazine full of everything, from world news to life’s great moments. Download Flipboard for free and search for “Harold Roman”

Theranos, the Hot Biotech Startup, Has a Huge Credibility Problem

Questions arise over whether the blood testing technology actually works.<p>The $9 billion Silicon Valley biotech startup Theranos received a slew of positive press since unveiling its products to the public two years ago, following a decade of working in secret. The company purports to have developed …

Genetic Engineering

Biotech stocks slide over prospect of price-controls

NEW YORK (AP) — Shares of biotechnology companies are tumbling over price-control concerns following Democratic presidential frontrunner Hillary …

Hillary Clinton

Warriors arena gets boost of support from biotech companies

Some of San Francisco’s biggest biotech firms went on record Wednesday as supporting the Golden State Warriors’ proposed arena, a development that proponents say “puts to rest” the idea that the life science industry is against the project.<p>In a letter to Warriors President <b>Rick Welts</b>, 13 companies …

San Francisco

Boom to bust: Biotech is now cutting jobs

The previously-booming biotech world is bracing for darker days ahead.<p>Biogen (BIIB), one of the sector's former darlings, announced plans on Wednesday to slash 11% of its workforce.<p>The belt tightening at Biogen is the latest sign of a changed environment for biotech. After incredible growth, the …

Spectrum says FDA declines to approve Evomela for injection

(Reuters) - Biotechnology company Spectrum Pharmaceuticals Inc said the U.S. Food and Drug Administration declined to approve its Evomela injection to treat patients with multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow.<p>Spectrum Pharmaceuticals said it …

FDA

As biotech selling spreads, more weakness seen for U.S. health stocks

NEW YORK (Reuters) - After a four-year love affair with healthcare shares, investors are moving on.<p>Selling has spread from biotechs - shaken on Sept. 21 when Hillary Clinton first tweeted concerns about drug prices - to other areas of the healthcare sector. Investors have been dumping shares of …

Stock Markets

Organs on Demand? 3D Printers Could Build Hearts, Arteries

Off-the-shelf 3D printers could one day help create living organs to aid in repairing the human body, researchers say.<p>Scientists have developed a way …

CORRECTED-Monsanto clears USDA regulatory hurdle for new GMO corn

(Corrects organization in sixth paragraph to Center for Food Safety from National Resources Defense Council)<p>By Karl Plume and P.J. Huffstutter<p>CHICAGO, Oct 23 (Reuters) - The U.S. Department of Agriculture on Friday signed off on a new genetically modified type of corn developed by Monsanto Co after …

Agriculture

Pfizer Loses U.K. Patent Case Over Lyrica

Drug maker had hoped for a ruling that would protect exclusive use for pain<p>LONDON—A U.K. High Court judge ruled against Pfizer Inc. in a closely watched patent case involving its blockbuster drug Lyrica, leaving generic-drug makers free to sell cheap copycats of the drug.<p>The New York-based drug …

Pfizer to sell Thane plant to Vidhi Research for Rs 178 crore

<b>New Delhi:</b> Drug firm Pfizer today said it has entered into a business transfer agreement to sell its Thane plant as a going concern to Vidhi Research …

Pfizer’s Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection

NEW YORK, Sep 24, 2015 (BUSINESS WIRE) -- Pfizer Inc. announced today that the company’s injectable contraceptive, Sayana®Press (medroxyprogesterone …

Pfizer India MD Aijaz Tobaccowalla resigns

Drug major Pfizer Ltd on Tuesday informed that its Managing Director Aijaz Tobaccowalla has resigned from the post.<p>The day-to-day operations of the …

FDA declines to expand approval of Pfizer arthritis drug

Oct 14 (Reuters) - U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker said on Wednesday.<p>Pfizer said it received a so-called complete response letter from the …

Pfizer

Pfizer says it could be leader in cancer with many new drugs

Drug giant Pfizer is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in …

Cancer

Pfizer loses U.K. patent case, opening door to cheap Lyrica copycat drugs

LONDON — A U.K. High Court judge ruled against Pfizer Inc. in a closely watched patent case involving its blockbuster drug Lyrica, leaving …

Patents

Pfizer says Hospira purchase will close in early September

NEW YORK (AP) — Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and …

Regeneron raises Eylea sales forecast, shares at record

(Reuters) - Regeneron Inc’s blockbuster eye drug, Eylea, showed no signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts’ expectation.<p>The company’s shares rose to a record of $605.93 in early trading on Tuesday.<p>U.S. sales of …

Macular Degeneration

Regeneron Pharmaceuticals Profit Doubles

Product revenue jumps 57% as U.S. sales of eye-treatment Eylea grow to $655 million<p>Regeneron Pharmaceuticals Inc., which recently won approval for its cholesterol drug, said profit doubled in its second quarter as sales of its eye-disease treatment surged.<p>Shares gained 2.4% in premarket …

Sanofi, Regeneron say new cholesterol drug data positive

PARIS (Reuters) - Sanofi and Regeneron Pharmaceuticals said on Tuesday that a study into their new cholesterol-lowering drug, Praluent, showed promising results.<p>“In a new pooled analysis of heterozygous familial hypercholesterolaemia (HeFH) patients ... Praluent significantly reduced bad …

FDA

Regeneron scientists discover key to excess bone growth in rare disease

CHICAGO (Reuters) - Scientists at U.S. biotechnology company Regeneron Pharmaceuticals researching a rare genetic disease that traps sufferers in a second skeleton have discovered a treatment that shuts down excessive bone growth in mice engineered to develop the illness.<p>Abnormal bone formation in …

Immune System

Regeneron Enters Agreement with BARDA on Antibody Therapy for Ebola | GEN

Click Image To Enlarge +<p>Source: Dream Designs/Shutterstock<p>×<p>Regeneron Pharmaceuticals signed an agreement with the Biomedical Advanced Research and …

Regeneron scientists discover key to excess bone growth in rare disease

Scientists at U.S. biotechnology company Regeneron Pharmaceuticals researching a rare genetic disease that traps sufferers in a second skeleton have discovered a treatment that shuts down excessive bone growth in mice engineered to develop the illness.<p>Company scientists said on Wednesday the …

Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?

Regeneron Pharmaceuticals has won a BARDA agreement to develop a potential vaccine for the Ebola virus. How big of a deal is it for Regeneron …

Novartis seeks approval for second Amgen biosimilar

The FDA has accepted Novartis’ submission for its biosimilar of Amgen’s Enbrel, which could mark the second time Amgen sees biosimilar competition …

Novartis biosimilar copycat takes aim at Amgen's drug Enbrel

ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis NOVN.VX unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s (AMGN.O) blockbuster Enbrel drug, the Swiss drugmaker said on Friday.<p>Swiss drugmaker Novartis' logo is seen behind scaffolding at …

FDA